The purpose of the Serum Markers and Rapid Triage Trial (SMART) is to evaluate the impact of serum markers of myocardial infarction on ED triage decision making when provided to """"""""clinicians in real time"""""""" (within approximately 15 minutes) using the Biosite Diagnostics Triage Cardiac System. The Triage Cardiac System is a fluorescence immunoassay used for the quantitative determination of CK-MB, Tropin I and Myoglobin. Patients will be enrolled in this study who present to the Emergency Departments with symptoms suggestive of acute cardiac ischemia (ACI- including chest pain, shortness of breath, upper abdominal pain, syncope, dizziness) who have an ECG ordered by the attending physician as part of the ED evaluation for possible cardiac ischemia. While serum markers of myocardial infarction are part of the routine evaluation of patients with suspected ACI, these results are not routinely used in the ED triage decision process because the results may take 1-3 hours to return form the laboratory. All consenting adult patients who have a blood sample obtained for the measurement of cardiac markers as part of the evaluation of possible ACI in the ED will be randomized to have cardiac marker results determined using the Biosite system in the ED (as well as the central Laboratory) as compared to standard care (results determined in central laboratory) The Biosite system provides results with in approximately 15 minutes. This study will measure the impact of these results on the accuracy of ED triage and treatment decisions for patients with suspected ACI. It has been suggested that serum markers may improve ED triage decisions by quickly identifying patients with myocardial damage, particularly in those patients where patients where the initial ECG is either non-diagnostic or misread by the clinician. This hypothesis has not been prospectively tested. Admitted patients will receive standard care. Patients who have cardiac markers obtained in the ED who are discharged home will return for follow-up studies to exclude missed MI. All patients will complete a 30 day follow up telephone call. All patients (admitted and discharged) who have not reached a predetermined end point (MI, cardiac cath, diagnostic study to exclude ACI) will be asked to return to to the HAC Heart station to have a stress cardiac scan.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000533-32
Application #
6409730
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
1978-12-01
Project End
2001-11-30
Budget Start
Budget End
Support Year
32
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Boston University
Department
Type
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Christensen, Kurt D; Uhlmann, Wendy R; Roberts, J Scott et al. (2018) A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. Genet Med 20:132-141
Kattan, Meyer; Bacharier, Leonard B; O'Connor, George T et al. (2018) Spirometry and Impulse Oscillometry in Preschool Children: Acceptability and Relationship to Maternal Smoking in Pregnancy. J Allergy Clin Immunol Pract 6:1596-1603.e6
Rhee, Rennie L; Davis, John C; Ding, Linna et al. (2018) The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. Clin J Am Soc Nephrol 13:251-257
Liebschutz, Jane M; Buchanan-Howland, Kathryn; Chen, Clara A et al. (2018) Childhood Trauma Questionnaire (CTQ) correlations with prospective violence assessment in a longitudinal cohort. Psychol Assess 30:841-845
Guan, Yue; Roter, Debra L; Wolff, Jennifer L et al. (2018) The impact of genetic counselors' use of facilitative strategies on cognitive and emotional processing of genetic risk disclosure for Alzheimer's disease. Patient Educ Couns 101:817-823
Altman, Matthew C; Whalen, Elizabeth; Togias, Alkis et al. (2018) Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma. J Allergy Clin Immunol 142:1856-1866
Berti, Alvise; Warner, Roscoe; Johnson, Kent et al. (2018) Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol 70:1114-1121
Wallace, Zachary S; Miloslavsky, Eli M; Cascino, Matthew et al. (2017) Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken) 69:1004-1010
Gern, James E; Calatroni, Agustin; Jaffee, Katy F et al. (2017) Patterns of immune development in urban preschoolers with recurrent wheeze and/or atopy. J Allergy Clin Immunol 140:836-844.e7
Guan, Yue; Roter, Debra L; Erby, Lori H et al. (2017) Disclosing genetic risk of Alzheimer's disease to cognitively impaired patients and visit companions: Findings from the REVEAL Study. Patient Educ Couns 100:927-935

Showing the most recent 10 out of 476 publications